about
The LMP2A ITAM is essential for providing B cells with development and survival signals in vivoBiology and disease associations of Epstein-Barr virus.Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase.Host factors LR1 and Sp1 regulate the Fp promoter of Epstein-Barr virus.Epstein-Barr virus latent membrane protein-2A-induced DeltaNp63alpha expression is associated with impaired epithelial-cell differentiationHigh cell density and latent membrane protein 1 expression induce cleavage of the mixed lineage leukemia gene at 11q23 in nasopharyngeal carcinoma cell line.Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.Enhanced IL-6/IL-6R signaling promotes growth and malignant properties in EBV-infected premalignant and cancerous nasopharyngeal epithelial cells.Primary lymphoepithelioma-like carcinoma of salivary glands: a clinicopathological study of 21 cases.Induction of Epstein-Barr virus (EBV) lytic cycle in vitro causes lipid peroxidation, protein oxidation and DNA damage in lymphoblastoid B cell linesUndifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia.Herpesvirus saimiri encodes a functional homolog of the human bcl-2 oncogeneNasopharyngeal carcinoma: an EBV-associated tumour not significantly influenced by HIV-induced immunosuppression. The AIDS/Cancer Working GroupKnockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through αv-integrin membrane translocation.An auto-regulatory loop for EBV LMP2A involves activation of Notch.Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor.Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic propertiesThe Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle.Chlorpyrifos Induces the Expression of the Epstein-Barr Virus Lytic Cycle Activator BZLF-1 via Reactive Oxygen Species.Functional differences between BHRF1, the Epstein-Barr virus-encoded Bcl-2 homologue, and Bcl-2 in human epithelial cells.Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV.Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins.The Translesion Polymerase Pol η Is Required for Efficient Epstein-Barr Virus Infectivity and Is Regulated by the Viral Deubiquitinating Enzyme BPLF1.The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility."The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection.Latent Epstein-Barr virus infection in cottontop tamarins. A possible model for Epstein-Barr virus infection in humans.Dysregulation of the MiR-449b target TGFBI alters the TGFβ pathway to induce cisplatin resistance in nasopharyngeal carcinoma.The Hsp70 inhibitor 2-phenylethynesulfonamide inhibits replication and carcinogenicity of Epstein-Barr virus by inhibiting the molecular chaperone function of Hsp70Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer
P2860
Q33604616-8705D86D-B2FB-4D76-A1C2-B5E71144ED13Q33772230-FB693F7B-268A-40BE-AE16-2E29E60F92E8Q33813796-D350BB3E-6C52-4479-9993-42C86055266EQ33965965-7B4AB88C-4F66-4428-9D9D-360D239250C4Q34029669-81EB87F8-7E1F-48B4-8CAA-5FD1E62C8370Q34198888-8BC45169-C0F9-4CDC-A1B6-345CA511A29EQ34350013-DB45608A-1C02-4E05-BE07-688548229747Q34712473-48EB6CB0-97D7-4159-A69D-068778699673Q34733299-4CA70E64-B518-4EBC-AF9C-71CDC16A07BFQ35137340-0D5C9DE2-EBAE-4281-832C-5CA97BBCC7BDQ35798133-7305162A-BB27-480F-8668-7BD76AF81719Q35884417-72A64BC3-16F3-4EEB-9077-C5C333C386F9Q36138669-B420FC27-6003-4F85-995F-FD7A1460D033Q36205880-A81C4AA1-D967-4841-AEFC-9D935236A348Q36276627-015C48D4-86E5-48A2-92D2-EB89448D89BFQ36528115-C80449D0-053E-4D67-863F-BD9B093F5C4EQ36668946-205CFBD6-ABBF-49BF-86DA-1AAF27D448C3Q37596432-6E8EFF21-4CCE-4F4B-A457-6D6FDA67A892Q38333491-1D65B568-3B89-4D28-BFB6-19AC2E5C5F34Q38844955-5B0EE88A-4577-4A14-86E1-CA73B7398C2EQ39582084-333A14A6-8C83-4E80-8AED-0E80EEEB64D4Q39599529-929EC801-BEB4-4422-A391-C1A32CBC9131Q39870850-45D9B7F3-B7EA-4B99-A2DE-F5740C8BE952Q40116028-DB12B859-4498-40FE-9FCE-5C8ABA208451Q40471301-CF4B5063-3577-4076-9E14-49295FE7A7CAQ40720231-5AAA4D27-9C05-4E5E-BAC8-F89880911D56Q41999096-37DADF7A-A61A-4A16-806D-36B4FA75B270Q42754184-3AA7321A-C2D8-43C1-B1F3-1359823CEFBDQ55001674-266E8813-ADDF-4437-8A57-7A4631B48883Q56476012-42541CB0-E822-4BB8-AFE8-720BD3C8269EQ56990996-DDD27F07-6462-49DC-9D48-2568BDE2FC66
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Epstein-Barr virus and nasopharyngeal carcinoma.
@ast
Epstein-Barr virus and nasopharyngeal carcinoma.
@en
type
label
Epstein-Barr virus and nasopharyngeal carcinoma.
@ast
Epstein-Barr virus and nasopharyngeal carcinoma.
@en
prefLabel
Epstein-Barr virus and nasopharyngeal carcinoma.
@ast
Epstein-Barr virus and nasopharyngeal carcinoma.
@en
P1476
Epstein-Barr virus and nasopharyngeal carcinoma.
@en
P2093
Raab-Traub N
P304
P577
1992-10-01T00:00:00Z